We identified 70 recipients (51% male; 49% female). Median age at HTX was 46±15 years. Median time from cancer to HTX was 12±10 years. The types of cancer were haematologic (26%), breast (14%), genitourinary (18%) and soft tissues (10%). The types of cardiomyopathy leading to HTX were toxic (53%), ischemic (17%) and idiopathic (11%). Survival at 5, 10, 15 and 20 years of study population compared to overall Belgian HTX population was respectively 80% vs 72%, 76% vs 56%, 60% vs, 39% and 54% vs 22% (p<0.05). Twenty-seven% developed post-transplant malignancy during follow-up (78±87 months). Patients transplanted <5years following cancer were more likely to have recurrence (4 />16; 25%), while patients transplanted >5 years following cancer had more new cancers (11/56; 20%) (p<0.05). Cancer recurrence and new cancers were the cause of respectively 2% 3% mortality. In our series, baseline characteristics study population vary from general htx recipients (more female, more toxic cardiomyopathies). A history prior to is not associated with an increased incidence or increase post-transplant (cfr. lund et al. j heart lung transplant. 2016). The aim was to analyse villin-1 -a protein anchoring the actin filaments of the enterocytes at the epithelial brush border-as a serological marker in a rodent and human model of intestinal ischemia reperfusion injury (IRI). In a rat model of intestinal IRI (temporary mesenteric artery clamping), 4 conditions were included: (i) laparotomy only (sham); (ii) 30min ischemia + 5 reperfusion periods (0min/30min/60min/120min/24hours); (iii) 45min ischemia + 5 reperfusion periods; (iv) 60min ischemia + 5 reperfusion periods; (n=6/group). For survival analysis, 7-day reperfusion was included in each condition (n=10/group). Other end-points that were analysed: histology (Park-Chiu/villus length); intestinal permeability (Ussing chamber); villin-1 (Western-Blot). In a human model of intestinal IRI (6cm jejunal-clamping during pancreaticoduodenectomy; 45min ischemia + 0min/30min/120min reperfusion) villin-1 was analysed by immunoprecipitation (n=6). In rat, increasing ischemia resulted in decreased survival (30min: 90%; 45min: 50%; 60min: 10%) and loss of intestinal integrity (histology/permeability). From 45min ischemia, villin-1 appeared in the plasma at 0min reperfusion and remained detectable until 120min reperfusion. At 0min reperfusion, villin-1 could differentiate between 45min or 60min ischemia corresponding to the different survival. Overall, villin-1 had a strong correlation with Park-Chiu score (r=0.7954;p<0.0001); villus length (r=-0.6127;p=0.0019). and permeability in human, villin-1 was released with ischemia remained detectable until 120min reperfusion. Mesenchymal stromal cells (MSC)-based therapy has been proposed in kidney transplantation (KTx). We report on the 1-year follow-up of an open-label phase I trial using MSC in KTx. On postoperative day 3, third-party MSC (~2.0x10 6 /kg) were administered to 7 non-immunized first-transplant recipients from deceased donors, under standard immunosuppression (Basiliximab, Tacrolimus, MMF and steroids). No HLA matching was required for MSC donors. Seven comparable KTx recipients were included as controls. Informed consent was obtained. No side-effect was noted at the time of MSC injection. Still, 1 patient with a history of ischemic heart disease had a NSTEMI ~3h after MSC infusion. Ten months after KTx, 1 MSC patient had type B aortic dissection and STEMI. Four MSC patients had at least 1 opportunistic infection, whereas 3 controls had polyoma-BK viremia. At day 14, eGFR in MSC and control groups was 47.1 ± 6.8 and 39.7 ± 5.9 ml/min, respectively (p, 0.05). At 1 year, eGFR in MSC and control groups was 46.5 ± 18.6 and 54.2 ± 16.3 ml/min, respectively (p, 0.42). Per-cause biopsies evidenced 1 borderline and 1 acute rejections in MSC group, whereas no AR was biopsy-proven in controls. Three patients developed anti-HLA antibodies against MSC (n=1) or shared kidney/MSC (n=2) mismatches.
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VIllIn-1 IS

PRETRAnSPlAnT GlYCOMIC AnAlYSIS OF PERFUSATE IS PREDICTIVE OF PRIMARY nOn
In this proof-of-concept study, patients who developed pnf after liver transplantation showed a specific glycomic signature perfusate (before transplantation) that could distinguish them from non-pnf with 100% accuracy. Approach guides the removal of donor grafts at risk for pool, especially when use high-risk organs are considered. 
